Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a Phase 2 clinical study titled A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer. The study aims to assess the safety and efficacy of telisotuzumab adizutecan, an investigational drug, in combination with other treatments for metastatic colorectal cancer (mCRC), a prevalent cancer worldwide.
The study tests telisotuzumab adizutecan, given intravenously, alongside established drugs like fluorouracil, leucovorin, oxaliplatin, bevacizumab, and panitumumab. These combinations aim to improve treatment outcomes for mCRC patients.
This interventional study is randomized with a parallel assignment. It is open-label, meaning both researchers and participants know the treatment being administered. The primary purpose is treatment-focused, aiming to find effective drug combinations for mCRC.
The study began on April 24, 2025, with primary completion expected in approximately six years. The last update was submitted on June 24, 2025, indicating ongoing recruitment and study activities.
For investors, this study could impact AbbVie’s stock performance and investor sentiment, especially if the results show significant improvements in mCRC treatment. The competitive landscape in oncology could see shifts depending on the study’s outcomes, affecting industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.